CMPS Stock Recent News

Although psychedelic drug stocks have lost some of their earlier momentum, significant research and advancements continue under the radar. Even high-profile figures like Elon Musk reportedly use ketamine for depression, highlighting the ongoing interest in non-standard treatment protocols often associated with psychedelic stocks (though ketamine itself isn't a psychedelic, it does fall within the “alternative therapeutics” camp that psychedelic drug stocks often occupy).

While the cannabis industry has all but become legitimate in the United States, it's not the only form of alternative medicine attempting to break through regulatory barriers. Compounds like psilocybin, lysergic acid and ketamine are all referred to as psychedelics, yet they may have medical applications which are just beginning to be explored.

LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Lori Englebert as Chief Commercial Officer, effective July 8, 2024. She will be based in the company's New York City office.

LONDON, June 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference at 7:00 am ET on June 27, 2024. The company will also participate in a panel discussion titled “Commercialization of Novel Compounds in Psychiatry” at 12:00pm ET on June 27, 2024.

Compass Pathways stock took a hit in early June. Lykos Therapeutics just got some extremely bearish news from regulators.

Compass Pathways will report some key data in Q4. One of its competitors will soon face a critical interaction with regulators.

COMPASS Pathways plc (NASDAQ:CMPS ) Q1 2024 Results Conference Call May 8, 2024 8:00 AM ET Company Participants Stephen Schultz - SVP, IR Kabir Nath - CEO Guy Goodwin - Chief Medical Officer Teri Loxam - CFO Conference Call Participants Vikram Purohit - Morgan Stanley Ritu Baral - TD Cowen Charles Duncan - Cantor Patrick Trucchio - H.C. Wainwright & Co. Tom Shrader - BTIG Sumant Kulkarni - Canaccord Genuity Elemer Piros - Rodman Operator Thank you for standing by, and welcome to the COMPASS Pathways' First Quarter 2024 Earning Investor Call [Operator instructions].

LONDON, May 03, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter 2024 ending March 31, 2024, and provide an update on recent business developments, on May 8, 2024.

Vertex Pharmaceuticals is angling to treat acute pain with its new drug. Compass Pathways will have a major data update sometime in Q4.

There are some great microcap stocks for investors to scoop up this month. The broader indices, such as the S&P 500 and the Nasdaq, are showing signs of both strength and weakness, but I believe that there's still a lot of gas left in the tank for these to surge higher.